Asia has been detected and is predicted to grow; therefore development of other treatments is highly desirable. 2 One promising antimalarial drug target that is being investigated is Pf cGMP-dependent protein kinase (PfPKG), an enzyme which is conserved to a high degree of homology in other species of therapeutic relevance such as P. vivax and P. berghei. This protein kinase is essential in all the key phases of the Pf parasite life cycle and in the blood stage, inhibiting PfPKG stops replication by preventing merozoite egress 3 and invasion. 4 First generation PfPKG inhibitors have also been shown to block gametogenesis 5 and ookinete motility 6 -two key developmental events required for mosquito-borne transmission. It has also been shown that PKG is essential for sporozoite motility and liver cell invasion 7 as well as late liver stage development, 8 making PfPKG an attractive target for new classes of anti-malarial drugs.
Herein, we will discuss PfPKG inhibitors derived from PKG inhibitors (compound 1 and 2) developed to treat Eimeria infections in poultry 9 (Figure 1 ). Both of these compounds showed low nanomolar potencies in a biochemical assay against PfPKG 10 and moderate potency in an in vitro cell viability assay, the hypoxanthine incorporation assay (HXI). This paper is focused on the monocyclic compound 1, containing a pyrrole and an unflanked 4-pyridyl, both considered undesirable motifs for further SAR development.
Furthermore, poor kinase selectivity was seen with 1, as it also showed potent activity against several other human kinases. Due to these unfavourable properties of 1, an alternative core was sought for further analogue development with the aim of enhancing anti-parasitical activity against PfPKG.
Literature searches on similar structures to compound 2 had showed examples where the imidazopyridine core could be swapped for a thiazole core, while still maintaining the interactions formed by the appended groups. 11 In addition, homology modelling (data not shown) indicated a good fit for our proposed compounds. With this knowledge, we swapped the monocyclic pyrrole core to a thiazole core, and the pyridine for the 2aminopyrimidine from compound 2, to give thiazole 3 ( Figure 2) .
Compound 3, when tested, showed similar biochemical potency and a slight drop in cellular potency when compared to compounds (1) and (2) ( Figure 2 ), which was seen as a positive result for the changed thiazole core. To optimize the potency, we first examined the pendent 2-aminopyrimidine (Scheme 1). Alkylation of 4 with benzoate 5 was achieved using LiHMDS to give ketone 6. This was then reacted with (Me)3SiCl and ( n Bu)4NBr to yield the α-chloro ketone in situ, which was cyclized with the Boc-protected thioamide in refluxing ethanol to give 7. Deprotection of 7, and subsequent reductive amination gave 8, and on oxidation, the resulting sulfone could be displaced by the appropriate amine to yield 9a-d. Two alternatives to the Nmethylpiperidine ring were also made. 9e was synthesized following sulfone oxidation of 7, with Boc deprotection occurring in the displacement step by the amine. 9f was synthesized from tert-butyl 3-carbamothioylpyrrolidine-1-carboxylate and 6 using similar chemistry. Introduction of a methyl group on the amino pyrimidine (9a) had little effect on potency but (Table 3) .
Methyl derivative (10) Replacement of the 4-fluoropenyl moiety with alkyl substituents gave rise to weakly active analogues (10, 11) which both showed a significant drop in biochemical potency when compared to 9c. The lower activity seen with the alkyl substituents could be attributed to their inability to sufficiently fill the hydrophobic pocket between the catalytic lysine (K570) and the small gatekeeper residue (T618) (Figure 3 ). Despite the binding potency of 11, it showed similar cellular potency to 9c, possibly resulting from poor kinase selectivity as 11
is capable of binding to kinases in the cell with larger gatekeepers. 14 Introduction of the sulfone (16a) gave a compound with comparable IC50 values to 9c, but with a much improved kinase selectivity profile ( Figure 5 ).
To further enhance the kinase selectivity of the compounds, additional analogues were made with groups of greater polarity in an attempt to capitalize on additional interactions with the PfPKG enzyme. The new analogues were synthesized with smaller alkyl groups on the pyrimidine ring instead of the large phenyl piperazine group (Table 3 ).
The synthesis of sulfonamide 23 is highlighted in Scheme 3. The nitroester (17) was hydrogenated to the aniline, and protected as the methyl carbamate to yield 18 which was subjected to subsequent ketone formation, then chlorination and cyclization to give thiazole 20. Boc deprotection and reductive amination, followed by hydrolysis with sodium hydroxide gave the unprotected aniline, 21.
Sulfonylation of 21 was carried out with two equivalents of methanesulfonyl chloride to give firstly the bis sulfonamide, which on exposure to excess sodium hydroxide, yielded the mono sulfonamide 22. Oxidation to the sulfone and displacement with cyclopropylmethylamine yielded 23. Replacement of the phenyl piperazine by a hydrogen to give the unsubstituted amino pyrimidine (16b) showed a drop in potency, due to the loss of the aforementioned charge interaction with D682. Small alkyl substituents on the amino pyrimidine with the methyl sulphone (16c-e) all showed good potency in the biochemical assay but this did not translate into good potency in the cell assay.
The fluorosulfonamide (23) was the most potent analogue in the biochemical assay and docking of this compound (as shown in Figure 4 ) revealed the additional polar interactions responsible. The cyclopropylmethyl efficiently fills the small hydrophobic pocket between V621 and Y822, whilst the sulphonamide forms H-bonds with the DFG loop and a charge interaction with K570. Additionally 23 showed very good selectivity against human kinases, likely arising from the small threonine gatekeeper residue as described earlier. Compound 23 and two
additional key examples were then profiled in a number of in vitro ADME assays (Table   4 ). Data for 9c showed a very good overall profile, good logD and stability along with good PAMPA and kinetic solubility. Despite an otherwise excellent profile, the LogD of 16a was low when measured, potentially contributing to the poor permeability seen. Compound 23 was found to be metabolically stable in human and mouse liver microsomes, and also showed good permeability ( 16 Red is >90% inhibition; yellow between 90% and 70% inhibition, green <70% inhibition, white-not tested Table 4 In vitro ADME data for compounds 9c, 16a and 23 Gutteridge and Simon Croft for many helpful discussions, and Jeremy Burrows and Sir Simon Campbell (Medicines for Malaria Venture) for their support of this work
